Shots: LCB to receive up front & milestone of ~$1027.5M upon achievement of development & regulatory milestones along with royalties on net sales. The deals also include ~$29.5M in upfront […]readmore
In an interview with PharmaShots, Christopher J. Calhoun, President & CEO at Paracrine shared his views on the transforming diabetes treatment with the first autologous, device-based cell therapy platform Shots: […]readmore
Shots: The new analysis from the clinical trial data evaluates Livmarli (IBAT inhibitor) vs natural history cohort in patients with alagille syndrome. The extensive real-world analysis conducted by GALA & […]readmore
Shots: The EC has granted marketing authorisation for Celltrion’s regdanvimab in adults with COVID-19 who do not require supplemental oxygen & are at high risk of progressing to severe COVID-19 […]readmore
Shots: The P-IIa EPICCURE trial evaluates safety, tolerability & exploratory efficacy of epicardial inj. of AZD8601 vs PBO in 11 patients (7 were treated with AZD8601 & 4 received PBO […]readmore
Shots: Entos will use its Fusogenix nucleic acid delivery system to develop BioMarin products for multiple genetic diseases. BioMarin will be responsible for the preclinical studies of the Fusogenix-formulated products […]readmore
Shots: The P-II AXIOMATIC-TKR study evaluates the efficacy and safety of milvexian (qd/bid) vs enoxaparin (SC) in 1242 patients with elective TKR surgery The trial met both of its pre-specified […]readmore
Shots: The designation is based on the results of the P-III JUPITER-06 clinical trial that evaluates toripalimab + CT vs CT alone in patients with advanced or metastatic ESCC The […]readmore
In an interview with PharmaShots, Jan van de Winkel, co-founder, President, and CEO at Genmab shared his views on the US FDA’s Accelerated Approval of Tivdak (tisotumab vedotin-tftv) for the […]readmore
Shots: AcelRx signs a merger agreement to acquire Lowell for $32.5M in cash and an additional ~$26.0M in contingent consideration upon the achievement of regulatory and sales-based milestones, $3.5M in […]readmore